Dendreon Corporation Announces Presentation Of PROVENGE® (sipuleucel-T) Data At The 2014 Genitourinary Cancer Symposium (ASCO GU)
Published: Jan 30, 2014
Dendreon Corporation (NASDAQ:DNDN) today announced the presentation of four PROVENGE® (sipuleucel-T) abstracts and one abstract for DN24-02, an investigational active cellular immunotherapy, from ongoing clinical trials at the 2014 Genitourinary Cancers Symposium (ASCO GU) from January 30-February 1, 2014 in San Francisco, California.
Help employers find you! Check out all the jobs and post your resume.